02Jun 2023
The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?

The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?

The FDA's Accelerated Approval pathway, which has facilitated early access to new oncology drugs, is facing criticism and undergoing potential reforms. In March 2023, the FDA released draft guidance offering solutions to enhance the pathway and improve patient outcomes in cancer treatment. While the Accelerated Approval pathway has successfully granted early access to innovative cancer medications, it has faced scrutiny due to withdrawals of approved indications and delays in completing confirmatory studies. These delays have allowed drugs to remain on the market without demonstrating conclusive clinical benefits. The new guidance addresses these issues and optimises the program's effectiveness.

  • #oncology

Like

Save

Share